MA47217A - Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique - Google Patents
Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatiqueInfo
- Publication number
- MA47217A MA47217A MA047217A MA47217A MA47217A MA 47217 A MA47217 A MA 47217A MA 047217 A MA047217 A MA 047217A MA 47217 A MA47217 A MA 47217A MA 47217 A MA47217 A MA 47217A
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- kallicrein
- plasmatic
- arylmethyl
- het
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000003827 Plasma Kallikrein Human genes 0.000 abstract 1
- 108090000113 Plasma Kallikrein Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des composés de formule (i), des compositions comprenant lesdits composés ; l'utilisation desdits composés en thérapie (par exemple dans le traitement ou la prévention d'une maladie ou d'un état avec implication de l'activité de la kallikréine plasmatique) ; et des méthodes de traitement de patients par lesdits composés ; r5, r6, r7, a, b, w, x, y et z étant tels que définis dans la description.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1421083.5A GB201421083D0 (en) | 2014-11-27 | 2014-11-27 | Enzyme inhibitors |
PCT/GB2015/053615 WO2016083820A1 (fr) | 2014-11-27 | 2015-11-26 | Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique |
Publications (2)
Publication Number | Publication Date |
---|---|
MA47217A true MA47217A (fr) | 2019-11-13 |
MA47217B1 MA47217B1 (fr) | 2021-04-30 |
Family
ID=52349552
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA47217A MA47217B1 (fr) | 2014-11-27 | 2015-11-26 | Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique |
MA41014A MA41014B1 (fr) | 2014-11-27 | 2015-11-26 | Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique |
MA52063A MA52063B1 (fr) | 2014-11-27 | 2015-11-26 | Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA41014A MA41014B1 (fr) | 2014-11-27 | 2015-11-26 | Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique |
MA52063A MA52063B1 (fr) | 2014-11-27 | 2015-11-26 | Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique |
Country Status (37)
Country | Link |
---|---|
US (6) | US10364238B2 (fr) |
EP (4) | EP3224256B1 (fr) |
JP (4) | JP6653702B2 (fr) |
KR (2) | KR102496404B1 (fr) |
CN (2) | CN107108576B (fr) |
AR (2) | AR102850A1 (fr) |
AU (2) | AU2015352193B2 (fr) |
BR (1) | BR112017010882B1 (fr) |
CA (1) | CA2967894C (fr) |
CL (1) | CL2017001362A1 (fr) |
CO (1) | CO2017006230A2 (fr) |
CY (3) | CY1122255T1 (fr) |
DK (3) | DK3556752T3 (fr) |
EC (1) | ECSP17039127A (fr) |
ES (3) | ES2745815T3 (fr) |
GB (1) | GB201421083D0 (fr) |
HK (1) | HK1244268A1 (fr) |
HR (3) | HRP20220314T1 (fr) |
HU (3) | HUE057647T2 (fr) |
IL (2) | IL278182B (fr) |
LT (3) | LT3556752T (fr) |
MA (3) | MA47217B1 (fr) |
MD (3) | MD3224256T2 (fr) |
ME (1) | ME03514B (fr) |
MX (2) | MX2020013038A (fr) |
MY (1) | MY176853A (fr) |
NZ (1) | NZ731945A (fr) |
PH (1) | PH12017500901A1 (fr) |
PL (3) | PL3556752T3 (fr) |
PT (3) | PT3224256T (fr) |
RS (3) | RS63155B1 (fr) |
RU (1) | RU2707870C2 (fr) |
SG (2) | SG10201907819WA (fr) |
SI (3) | SI3556752T1 (fr) |
TW (2) | TWI741377B (fr) |
UA (1) | UA123087C2 (fr) |
WO (1) | WO2016083820A1 (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
GB201421083D0 (en) * | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
EP3355890B1 (fr) | 2015-10-01 | 2021-11-10 | Biocryst Pharmaceuticals, Inc. | Inhibiteurs de la kallicréine plasmatique humaine |
GB201609519D0 (en) * | 2016-05-31 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide |
US11180484B2 (en) * | 2016-05-31 | 2021-11-23 | Kalvista Pharmaceuticals Limited | Pyrazole derivatives as plasma kallikrein inhibitors |
GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
GB201609607D0 (en) * | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
US11168080B2 (en) | 2017-04-26 | 2021-11-09 | Mitobridge, Inc. | Dynamin-1-like protein inhibitors |
GB201719882D0 (en) * | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of a plasma kallikrein inhibitor and salts thereof |
GB201721515D0 (en) * | 2017-12-21 | 2018-02-07 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibtor |
RS63069B1 (sr) | 2017-11-29 | 2022-04-29 | Kalvista Pharmaceuticals Ltd | Dozni oblici koji sadrže inhibitor kalikreina plazme |
GB201719881D0 (en) * | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
WO2019106359A1 (fr) * | 2017-11-29 | 2019-06-06 | Kalvista Pharmaceuticals Limited | Inhibiteurs d'enzymes |
EP3765459A1 (fr) | 2018-03-13 | 2021-01-20 | Shire Human Genetic Therapies, Inc. | Imidazopyridines substituées en tant qu'inhibiteurs de la kallicréine plasmatique et leurs utilisations |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
GB201910116D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
GB201910125D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of angioedema |
WO2021028645A1 (fr) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Inhibiteurs de la kallicréine plasmatique |
EP4031245A1 (fr) | 2019-09-18 | 2022-07-27 | Takeda Pharmaceutical Company Limited | Inhibiteurs hétéroaryles de la kallicréine plasmatique |
EP4031547B1 (fr) | 2019-09-18 | 2024-07-17 | Takeda Pharmaceutical Company Limited | Inhibiteurs de la kallicréine plasmatique et leurs utilisations |
CN113004286B (zh) * | 2019-12-20 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为血浆激肽释放酶抑制剂的三环类化合物及其用途 |
TW202144331A (zh) * | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
CN115210230A (zh) * | 2020-03-04 | 2022-10-18 | 南京明德新药研发有限公司 | 杂环类化合物 |
TW202228686A (zh) | 2020-10-15 | 2022-08-01 | 英商卡爾維斯塔製藥有限公司 | 血管性水腫之治療 |
US20230381162A1 (en) | 2020-10-23 | 2023-11-30 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
US20240122909A1 (en) | 2021-02-09 | 2024-04-18 | Kalvista Pharmaceuticals Limited | Treatments of hereditary angioedema |
WO2023002219A1 (fr) | 2021-07-23 | 2023-01-26 | Kalvista Pharmaceuticals Limited | Traitements de l'angio-oedème héréditaire |
WO2023185634A1 (fr) * | 2022-03-30 | 2023-10-05 | 南京明德新药研发有限公司 | Composé hétérocyclique utilisé comme inhibiteur de la kallicréine plasmatique |
EP4288036A1 (fr) | 2022-04-27 | 2023-12-13 | Kalvista Pharmaceuticals Limited | Formulations d'un inhibiteur de la kallicréine plasmatique |
WO2024025907A1 (fr) * | 2022-07-29 | 2024-02-01 | Rezolute, Inc. | Inhibiteurs de la kallicréine plasmatique |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
US5786328A (en) | 1995-06-05 | 1998-07-28 | Genentech, Inc. | Use of kunitz type plasma kallikrein inhibitors |
US7101878B1 (en) | 1998-08-20 | 2006-09-05 | Agouron Pharmaceuticals, Inc. | Non-peptide GNRH agents, methods and intermediates for their preparation |
EP3222619A1 (fr) * | 1999-04-15 | 2017-09-27 | Bristol-Myers Squibb Holdings Ireland | Inhibiteurs cycliques de la protéine tyrosine kinase |
US7232819B2 (en) | 2001-10-26 | 2007-06-19 | Istituto Di Ricerche Di Biologia P. Angeletti S.P.A. | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase |
ATE455104T1 (de) | 2001-11-01 | 2010-01-15 | Icagen Inc | Pyrazolamide zur anwendung in der behandlung von schmerz |
GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
PE20040600A1 (es) | 2002-04-26 | 2004-09-15 | Lilly Co Eli | Derivados de triazol como antagonistas del receptor de taquicinina |
EP1426364A1 (fr) | 2002-12-04 | 2004-06-09 | Aventis Pharma Deutschland GmbH | Dérivés d'imidazole comme inhibiteurs du facteur Xa |
DE10301300B4 (de) | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
AU2004209456A1 (en) | 2003-02-03 | 2004-08-19 | Janssen Pharmaceutica N.V. | Quinoline-derived amide modulators of vanilloid VR1 receptor |
DK1660057T3 (da) | 2003-08-27 | 2012-08-20 | Ophthotech Corp | Kombinationsterapi til behandling af neovaskulære øjenlidelser |
TW200526588A (en) * | 2003-11-17 | 2005-08-16 | Smithkline Beecham Corp | Chemical compounds |
GB0403155D0 (en) | 2004-02-12 | 2004-03-17 | Vernalis Res Ltd | Chemical compounds |
EP1568698A1 (fr) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Dérivés de pyrrole en tant qu'inhibiteurs du facteur xa |
US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
CN101018788B (zh) | 2004-09-03 | 2010-08-25 | 株式会社柳韩洋行 | 吡咯并[3,2-c]吡啶衍生物及其制备方法 |
EP2500031A3 (fr) | 2005-02-24 | 2012-12-26 | Joslin Diabetes Center, Inc. | Compositions et procédés de traitement de la perméabilité vasculaire |
GB0508472D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
KR101142363B1 (ko) | 2005-06-27 | 2012-05-21 | 주식회사유한양행 | 피롤로피리딘 유도체를 포함하는 항암제 조성물 |
WO2007011328A1 (fr) * | 2005-07-14 | 2007-01-25 | Jackson Kenneth A | Procédé d’inhibition d’aiguille hypodermique après utilisation |
BRPI0613429A2 (pt) | 2005-07-14 | 2009-02-10 | Takeda San Diego Inc | inibidores de histona desacetilase |
US20070254894A1 (en) | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
GB0606876D0 (en) | 2006-04-05 | 2006-05-17 | Glaxo Group Ltd | Compounds |
US20070258976A1 (en) | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
EA016076B1 (ru) | 2006-07-06 | 2012-01-30 | Глэксо Груп Лимитед | Замещенные n-фенилметил-5-оксопролин-2-амиды в качестве антагонистов р2х7-рецептора и способы их применения |
CA2658523C (fr) | 2006-07-31 | 2012-06-12 | Activesite Pharmaceuticals, Inc. | Inhibiteurs de kallicreine plasmatique |
DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
EP2439205B1 (fr) | 2006-12-29 | 2015-03-11 | AbbVie Deutschland GmbH & Co KG | Composés de type carboxamide et leur utilisation comme inhibiteurs des calpaines |
US20100119512A1 (en) | 2007-01-25 | 2010-05-13 | Joslin Diabetes Center | Methods of diagnosing, treating, and preventing increased vascular permeability |
EP2125816A2 (fr) | 2007-03-07 | 2009-12-02 | Alantos Pharmaceuticals Holding, Inc. | Inhibiteurs de métalloprotéase contenant une fraction hétérocyclique |
MX2009009443A (es) | 2007-03-30 | 2009-09-14 | Sanofi Aventis | Compuestos de pirimidina hidrazida como inhibidores de pgds. |
BRPI0809930A2 (pt) | 2007-04-03 | 2014-10-07 | Glaxo Group Ltd | Derivados de carboxamida imidazolidina como moduladores de p2x7 |
CN101778827B (zh) | 2007-07-26 | 2012-10-10 | 先正达参股股份有限公司 | 杀微生物剂 |
US20110105567A1 (en) | 2007-08-22 | 2011-05-05 | Allergan, Inc. | Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity |
CA2709784A1 (fr) | 2007-12-21 | 2009-07-09 | University Of Rochester | Procede permettant de modifier la duree de vie d'organismes eucaryotes |
WO2009083553A1 (fr) | 2007-12-31 | 2009-07-09 | Rheoscience A/S | Composés azines en tant qu'activateurs de glucokinase |
US8658685B2 (en) | 2008-01-31 | 2014-02-25 | Activesite Pharmaceuticals, Inc. | Methods for treatment of kallikrein-related disorders |
WO2009106980A2 (fr) | 2008-02-29 | 2009-09-03 | Pfizer Inc. | Dérivés d'indazole |
ATE543811T1 (de) | 2008-03-13 | 2012-02-15 | Bristol Myers Squibb Co | Pyridazinderivate als faktor-xia-inhibitoren |
SI2308838T1 (sl) | 2008-07-08 | 2016-09-30 | Daiichi Sankyo Company, Limited | Dušik vsebujoča aromatska heterociklična spojina |
US8324385B2 (en) | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
BR112012014990A2 (pt) | 2009-12-18 | 2016-04-05 | Activesite Pharmaceuticals Inc | composto, método para tratar uma doença ou condição dependente de calicreína de plasma, e, composição. |
JP2011157349A (ja) | 2010-01-07 | 2011-08-18 | Daiichi Sankyo Co Ltd | 含窒素芳香族ヘテロシクリル化合物を含有する医薬組成物 |
CA2788417C (fr) | 2010-01-28 | 2017-02-14 | The Medicines Company (Leipzig) Gmbh | Inhibiteurs de serine protease de type trypsine, et leur preparation et utilisation |
JP2013121919A (ja) | 2010-03-25 | 2013-06-20 | Astellas Pharma Inc | 血漿カリクレイン阻害剤 |
US8921319B2 (en) | 2010-07-07 | 2014-12-30 | The Medicines Company (Leipzig) Gmbh | Serine protease inhibitors |
WO2012009009A2 (fr) | 2010-07-14 | 2012-01-19 | Addex Pharma S.A. | Nouveaux dérivés de 2-amino-4-pyrazolyl-thiazole et leur utilisation en tant que modulateurs allostériques des récepteurs métabotropiques du glutamate |
US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
EP2458315B1 (fr) | 2010-11-25 | 2017-01-04 | Balcke-Dürr GmbH | Echangeur thermique régénératif doté d'un joint de rotor forcé |
US8691861B2 (en) | 2011-04-13 | 2014-04-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
US9133128B2 (en) | 2011-06-17 | 2015-09-15 | Research Triangle Institute | Pyrazole derivatives as cannabinoid receptor 1 antagonists |
GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
WO2013048982A1 (fr) | 2011-09-27 | 2013-04-04 | Bristol-Myers Squibb Company | Composés de pyrrolinone-carboxamide utiles en tant qu'inhibiteurs de lipase endothéliale |
EP2760828B1 (fr) | 2011-09-27 | 2015-10-21 | Bristol-Myers Squibb Company | Composés de pyrrolinone-carboxamide utiles en tant qu'inhibiteurs de lipase endothéliale |
US20140378474A1 (en) | 2012-01-27 | 2014-12-25 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
EP2807156A1 (fr) | 2012-01-27 | 2014-12-03 | Novartis AG | Dérivés d'aminopyridine utilisés en tant qu'inhibiteurs de la kallicréine plasmatique |
US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2013130603A1 (fr) | 2012-02-27 | 2013-09-06 | Board Of Regents, The University Of Texas System | Ganglioside gd2 en tant que marqueur et cible sur des cellules souches cancéreuses |
GB201212081D0 (en) | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
CN104918942A (zh) | 2013-01-08 | 2015-09-16 | 萨维拉制药有限公司 | 嘧啶酮衍生物和它们用于治疗、改善或预防病毒疾病的用途 |
GB2510407A (en) | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
KR102523810B1 (ko) | 2013-01-20 | 2023-04-21 | 다케다 파머수티컬 컴패니 리미티드 | 브래디키닌 매개 장애의 평가 및 치료 |
MX2015012867A (es) | 2013-03-15 | 2016-06-10 | Verseon Corp | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. |
AU2014270152B9 (en) | 2013-05-23 | 2018-03-08 | Kalvista Pharmaceuticals Limited | Heterocyclic derivates |
CN105683179B (zh) | 2013-08-14 | 2018-10-26 | 卡尔维斯塔制药有限公司 | 血浆激肽释放酶的抑制剂 |
GB2517908A (en) | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
BR112016015449A8 (pt) | 2013-12-30 | 2020-06-09 | Lifesci Pharmaceuticals Inc | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos |
US9611252B2 (en) | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
BR112016020199A8 (pt) | 2014-03-07 | 2021-07-20 | Biocryst Pharm Inc | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso |
US9695166B2 (en) | 2014-05-05 | 2017-07-04 | Global Blood Therapeutics, Inc. | Pyrazolopyridine pyrazolopyrimidine and related compounds |
WO2015171526A2 (fr) | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Composés de pyrazolopyridine tricycliques |
JP6951970B2 (ja) | 2014-07-16 | 2021-10-20 | ライフサイ ファーマシューティカルズ,インク. | 治療用阻害化合物 |
CA2959026C (fr) | 2014-08-22 | 2023-10-24 | Biocryst Pharmaceuticals, Inc. | Compositions et utilisations de derives d'amidine |
WO2016044662A1 (fr) | 2014-09-17 | 2016-03-24 | Verseon Corporation | Composés de pyridone substituée par pyrazolyl en tant qu'inhibiteurs de sérine protéase |
GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
SG10201907699YA (en) | 2015-02-27 | 2019-09-27 | Verseon Corp | Substituted pyrazole compounds as serine protease inhibitors |
CA2991174A1 (fr) | 2015-07-01 | 2017-01-05 | Lifesci Pharmaceuticals, Inc. | Composes inhibiteurs therapeutiques |
CA2991171A1 (fr) | 2015-07-01 | 2017-01-05 | Lifesci Pharmaceuticals, Inc. | Composes inhibiteurs therapeutiques |
EP3368524B1 (fr) | 2015-10-27 | 2021-08-18 | Boehringer Ingelheim International GmbH | Utilisation de dérivés hétéroarylcarboxamides comme inhibiteurs de la kallicréine plasmatique |
EP3368529B1 (fr) | 2015-10-27 | 2022-04-06 | Boehringer Ingelheim International GmbH | Utilisation de dérivés hétéroarylcarboxamides comme inhibiteurs de la kallicréine plasmatique |
GB201609519D0 (en) | 2016-05-31 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide |
US11180484B2 (en) | 2016-05-31 | 2021-11-23 | Kalvista Pharmaceuticals Limited | Pyrazole derivatives as plasma kallikrein inhibitors |
GB201609602D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Chemical compounds |
GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
EP3481391A4 (fr) | 2016-07-11 | 2020-03-11 | Lifesci Pharmaceuticals, Inc. | Composés inhibiteurs thérapeutiques |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
GB201719882D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of a plasma kallikrein inhibitor and salts thereof |
WO2019106359A1 (fr) | 2017-11-29 | 2019-06-06 | Kalvista Pharmaceuticals Limited | Inhibiteurs d'enzymes |
-
2014
- 2014-11-27 GB GBGB1421083.5A patent/GB201421083D0/en not_active Ceased
-
2015
- 2015-11-26 US US15/527,923 patent/US10364238B2/en active Active
- 2015-11-26 RS RS20220301A patent/RS63155B1/sr unknown
- 2015-11-26 DK DK19176610.4T patent/DK3556752T3/da active
- 2015-11-26 EP EP15804210.1A patent/EP3224256B1/fr active Active
- 2015-11-26 SG SG10201907819WA patent/SG10201907819WA/en unknown
- 2015-11-26 MD MDE20170127T patent/MD3224256T2/ro unknown
- 2015-11-26 IL IL278182A patent/IL278182B/en unknown
- 2015-11-26 MX MX2020013038A patent/MX2020013038A/es unknown
- 2015-11-26 CN CN201580071671.XA patent/CN107108576B/zh active Active
- 2015-11-26 DK DK15804210.1T patent/DK3224256T3/da active
- 2015-11-26 ES ES15804210T patent/ES2745815T3/es active Active
- 2015-11-26 MX MX2017006823A patent/MX2017006823A/es unknown
- 2015-11-26 LT LTEP19176610.4T patent/LT3556752T/lt unknown
- 2015-11-26 LT LTEP15804210.1T patent/LT3224256T/lt unknown
- 2015-11-26 JP JP2017527570A patent/JP6653702B2/ja active Active
- 2015-11-26 SG SG11201703988PA patent/SG11201703988PA/en unknown
- 2015-11-26 MY MYPI2017701845A patent/MY176853A/en unknown
- 2015-11-26 PT PT15804210T patent/PT3224256T/pt unknown
- 2015-11-26 HU HUE19176610A patent/HUE057647T2/hu unknown
- 2015-11-26 RU RU2017122364A patent/RU2707870C2/ru active
- 2015-11-26 AU AU2015352193A patent/AU2015352193B2/en active Active
- 2015-11-26 EP EP19176610.4A patent/EP3556752B1/fr active Active
- 2015-11-26 EP EP21215491.8A patent/EP4039681A1/fr active Pending
- 2015-11-26 KR KR1020217018472A patent/KR102496404B1/ko active IP Right Grant
- 2015-11-26 DK DK19182383.0T patent/DK3567037T3/da active
- 2015-11-26 MD MDE20191218T patent/MD3556752T2/ro unknown
- 2015-11-26 UA UAA201706473A patent/UA123087C2/uk unknown
- 2015-11-26 SI SI201531813T patent/SI3556752T1/sl unknown
- 2015-11-26 AR ARP150103900A patent/AR102850A1/es unknown
- 2015-11-26 MA MA47217A patent/MA47217B1/fr unknown
- 2015-11-26 RS RS20210205A patent/RS61497B1/sr unknown
- 2015-11-26 PL PL19176610T patent/PL3556752T3/pl unknown
- 2015-11-26 MA MA41014A patent/MA41014B1/fr unknown
- 2015-11-26 HU HUE19182383A patent/HUE053317T2/hu unknown
- 2015-11-26 ES ES19176610T patent/ES2908303T3/es active Active
- 2015-11-26 BR BR112017010882-8A patent/BR112017010882B1/pt active IP Right Grant
- 2015-11-26 SI SI201530836T patent/SI3224256T1/sl unknown
- 2015-11-26 HR HRP20220314TT patent/HRP20220314T1/hr unknown
- 2015-11-26 ME MEP-2019-234A patent/ME03514B/fr unknown
- 2015-11-26 MD MDE20191295T patent/MD3567037T2/ro unknown
- 2015-11-26 HU HUE15804210A patent/HUE047425T2/hu unknown
- 2015-11-26 SI SI201531527T patent/SI3567037T1/sl unknown
- 2015-11-26 MA MA52063A patent/MA52063B1/fr unknown
- 2015-11-26 EP EP19182383.0A patent/EP3567037B1/fr active Active
- 2015-11-26 NZ NZ731945A patent/NZ731945A/en unknown
- 2015-11-26 PT PT191766104T patent/PT3556752T/pt unknown
- 2015-11-26 PL PL19182383T patent/PL3567037T3/pl unknown
- 2015-11-26 ES ES19182383T patent/ES2858082T3/es active Active
- 2015-11-26 WO PCT/GB2015/053615 patent/WO2016083820A1/fr active Application Filing
- 2015-11-26 PL PL15804210T patent/PL3224256T3/pl unknown
- 2015-11-26 RS RSP20191116 patent/RS59395B1/sr unknown
- 2015-11-26 PT PT191823830T patent/PT3567037T/pt unknown
- 2015-11-26 CN CN201910782520.5A patent/CN110577519A/zh active Pending
- 2015-11-26 CA CA2967894A patent/CA2967894C/fr active Active
- 2015-11-26 KR KR1020177017538A patent/KR102267623B1/ko active IP Right Grant
- 2015-11-26 LT LTEP19182383.0T patent/LT3567037T/lt unknown
- 2015-11-27 TW TW108135558A patent/TWI741377B/zh active
- 2015-11-27 TW TW104139776A patent/TWI686383B/zh active
-
2017
- 2017-05-15 PH PH12017500901A patent/PH12017500901A1/en unknown
- 2017-05-15 IL IL252287A patent/IL252287B/en active IP Right Grant
- 2017-05-26 CL CL2017001362A patent/CL2017001362A1/es unknown
- 2017-06-22 EC ECIEPI201739127A patent/ECSP17039127A/es unknown
- 2017-06-23 CO CONC2017/0006230A patent/CO2017006230A2/es unknown
-
2018
- 2018-03-15 HK HK18103626.6A patent/HK1244268A1/zh unknown
-
2019
- 2019-06-11 US US16/438,061 patent/US11001578B2/en active Active
- 2019-07-02 US US16/460,630 patent/US10611758B2/en active Active
- 2019-08-23 HR HRP20191524 patent/HRP20191524T1/hr unknown
- 2019-09-30 CY CY20191101020T patent/CY1122255T1/el unknown
- 2019-10-02 AU AU2019240616A patent/AU2019240616B2/en active Active
- 2019-10-08 JP JP2019184938A patent/JP6995101B2/ja active Active
-
2020
- 2020-02-28 US US16/804,872 patent/US11198691B2/en active Active
- 2020-07-31 US US16/944,658 patent/US11084809B2/en active Active
-
2021
- 2021-02-04 AR ARP210100300A patent/AR121273A2/es active IP Right Grant
- 2021-03-01 HR HRP20210350TT patent/HRP20210350T1/hr unknown
- 2021-03-08 CY CY20211100194T patent/CY1124046T1/el unknown
- 2021-07-28 JP JP2021123024A patent/JP7148683B2/ja active Active
- 2021-10-20 US US17/506,261 patent/US20220289729A1/en not_active Abandoned
-
2022
- 2022-03-11 CY CY20221100202T patent/CY1125214T1/el unknown
- 2022-09-21 JP JP2022149897A patent/JP2022180520A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47217A (fr) | Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique | |
PH12018502355A1 (en) | Enzyme inhibitors | |
MA40290A1 (fr) | Agents immunorégulateurs | |
PH12015502549A1 (en) | Heterocyclic derivatives | |
MA38483A1 (fr) | Inhibiteurs de l'ido | |
MA38810B1 (fr) | Inhibiteurs de rorc2 méthodes d'utilisation associées | |
MA47356A1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
MA44948A1 (fr) | Inhibiteurs de bace 1 | |
MA47736B1 (fr) | Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1 | |
MA40221A (fr) | Dérivés d'isoindoline à utiliser dans le traitement d'une infection virale | |
MX2022000545A (es) | Inhibidores de enzimas. | |
MA38009A1 (fr) | Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer | |
MA37849A1 (fr) | Dérivés de diazépinone à utiliser pour le traitement du syndrome de l'x fragile, de la maladie de parkinson ou de la maladie du reflux | |
MA45127B1 (fr) | Dérivés de pyrazole comme inhibiteurs de la kallikréine plasmatique | |
MA39260A1 (fr) | (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c | |
MA47036B1 (fr) | Agents immunoregulateurs | |
MA39506A1 (fr) | Dérivés de 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phényl)-urée utilisés comme inhibiteurs de cxcr2 | |
MA39719B1 (fr) | Pyrazoles substitués par un trifluoromethyle en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
MA39446A1 (fr) | Compositions pharmaceutiques pour traiter des maladies infecteuses | |
MA39204A1 (fr) | Derives hétéroaryles inhibiteurs de vps34 et/ou de p13 pour le traitement de troubles proliferatifs, inflammatoires ou cardiovasculaires | |
MA38473A1 (fr) | (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c |